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Summary
The avascular necrosis of bone is characterized by an abnor-
mality of tissue that can occur whenever a disease process
causes major cell stress. Some evidence supports a role for
genetic factors in some avascular necrosis suggesting that
gene mutations could play a role in the pathogenesis of os-
teonecrosis. These genetic studies provide hope that tools
for identifying high risk patients will be available in the fu-
ture.
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The term “avascular necrosis (AVN) of bone” is often used im-
properly to designate any bone lesion that contains some histo-
logical evidence of necrosis or that is misinterpreted as exhibit-
ing imaging features of AVN. Bone tissue necrosis is a non
specific abnormality that can occur whenever a disease
process causes major cell stress (1). 
So far, there is not accepted definition of osteonecrosis of jaw
(ONJ). However, clinically it typically appears as an area of
exposed alveolar bone that can occur in the mandibule or the
maxilla (2). It may or may not be painful and may or may not
be associated with infection or local trauma. Some evidence
supports a role for genetic factors in some of avascular
necrosis. 
Sickle cell anemia results from homozygosity for the Glu6Val
mutation in the hemoglobin beta chain gene (HBB) (3). Os-
teonecrosis is a common sequela of sickle cell disease and
several studies indicate that by the age of 35 years, one half
of all patients with this disease have osteonecrosis (4). Bald-
win et al. hypothesized that the presence or absence of os-
teonecrosis could be influenced by genetic variability in
genes other than HBB that are expressed in either bone or
vasculature (3). They examined the potential association of
osteonecrosis with single nucleotide polymorphisms (SNPs)
in candidate genes of different functional classes, including
those involved in vascular function, inflammation, oxidant
stress, and endothelial cell biology. SNPs in three genes
were found associated with the development of osteonecro-
sis. These genes are important in bone metabolism. In partic-
ular, KL gene encodes a glycosyl hydrolase that participates
in a negative regulatory network of the vitamin D endocrine
system and may be important for a wide variety of other cellu-
lar processes, including regulation of antioxidative defense,
angiotensin converting enzyme activity, arteriosclerosis, and
aging (5). Bone morphogenic proteins (BMPs) genes, includ-
ing BMP6 gene, encoding for pleiotropic secreted proteins
structurally related to transforming growth factor β (TGFβ)
and activins. BMP6 is involved in inflammatory processes (6)
and is important for bone formation and, in association with
parathyroid hormone (PTH) and vitamin D, appears to be in-
volved in inducing bone development by human bone mar-
row-derived mesenchymal stem cells (7). ANXA2 gene en-
coding for a member of the calcium-dependent phospholipid-
binding protein family and regulates cell growth and is in-
volved in signal transduction pathways (8). 
Although several genes have been identified that may play a
significant role in the pathogenesis of sickle cell osteonecrosis
by altering protein function of gene expression, the role of
these polymorphisms in the pathogenesis of the sickle cell os-
teonecrosis is not known. However these data may suggests
that the vascular complications due to the presence of “genetic
risk factors“ may improve the possibility to develop an os-
teonecrosis in patient affected by sickle cell disease. 
Hypercoagulability has been identified recently as a possible
contributor to AVN. Procoagulant abnormalities have been
found in patients with AVN or Legg Perthes disease (9). Glueck
et al. (10) assessed whether heterozygosity for the throm-
bophilic Leiden mutation of the factor V gene (MFV) was patho-
genic for alveolar osteonecrosis of the jaw and whether a syn-
ergism between exogenous estrogens and MFV for develop-
ment of osteonecrosis was present. They found that subjects
with MFV have a higher risk both for venous thrombosis and
osteonecrosis and in these subjects the use of oral contracep-
tives may be contraindicated (10). 
Primary thrombophilia and hyperfibrinolysis appear to be
common, heritable, pathophysiologic risk factors for idiopathic
osateoncerosis of the jaws (11). In addition, factor V Leiden,
a genetic risk factor for venous thrombosis, has been associ-
ated with non traumatic osteonecrosis of the femoral head,
supporting the hypothesis that intravascular coagulation is a
major pathogenetic mechanism of the disease (12). Recently
coagulation abnormalities in the form of factor V Leiden and
the prothrombin 20210A gene mutations have been associat-
ed also with a higher incidence of osteonecrosis of the knee
(13).
Osteonecrosis of the femoral head also occurs in association
with corticosteroid treatment. The pathology of femoral head
osteonecrosis has not been fully clarified, but it is though
those drastic ischemic changes occur in femoral head and
then bone necrosis develops (14). Several studies have re-
ported a relationship between plasma lipoprotein(a) [Lp(a)]
concentration and vascular lesions such as coronary heart
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disease, stroke and carotid atherosclerosis (15). Lp(a) is a
low-density lipoprotein (LDL)-like lipoprotein that has a com-
ponent of two disulfile-linked high molecular weight proteins,
apolipoprotein(a) and apolipoprotein B100. Apo(a) is consid-
ered a lipoprotein that induces both artheriosclerosis and
thrombogenesis (16). 
Testsurom et al. (14) examined the relationship between corti-
costeroid-induced femoral head osteonecrosis after renal
transplantation in Japanese patients and apo(a) gene polymor-
phism. They found that subjects with gene haplotype CC had
significantly higher plasma Lp(a) levels than those with gene
haplotype DD. In addition, they found that the risk of os-
teonecrosis was high in patients with low molecular weight
apo(a) isoforms (14). In a study of 136 renal transplant recipi-
ents, the risk of AVN was closely dependent on the multidrug
resistance (MDR) gene, of which the ABCB1 C3435 TT haplo-
type was strongly protective (odds ratio, 0.10) (17). This haplo-
type was associated with decreased intracellular concentra-
tions of glucocorticoids (1, 17).
Some genes involved in the pathogenesis of AVN are repre-
sented by the ADH2, ADH3, ALDH2 and P450E1. These
genes are involved in the alcohol metabolism and polymor-
phisms of these genes have been associated with the risk of
AVN. In particular, analysis revealed that ADH2*1 allele may
diminish the risk of AVN related to alcohol abuse (18).
In Taiwan, Chen et al. (19) identified two families with ANV of
the femoral head (ANFH) showing autosomal dominant inheri-
tance. By linkage analysis in a 4-generation family, they ex-
cluded linkage with antithrombotic protein C (PROC), protein S
(PROS1), and PAI, which had been implicated in thrombophilia
or hypofibrinolysis. Furthermore, by a genome-wide scan, a
significant 2-point lod score of 3.45 (theta = 0.0) was obtained
between ANFH and marker D12S85 on chromosome 12. High-
resolution mapping was conducted in a second family with
ANFH, with replication of the linkage to D12S368. When an
age-dependent penetrance model was applied, the combined
multipoint lod score was 6.43 between D12S1663 and
D12S85, a 15-cM region on 12q13 (19). Liu et al. identified
three families in which there was autosomal dominant inheri-
tance of ANFH, with mapping of the phenotype to 12q13. They
carried out haplotype analysis in the families, selected candi-
date genes in the critical interval for ANFH on 12q13, and se-
quenced the promoter and exonic regions of the type II colla-
gen gene (COL2A1) from patients with inherited and sporadic
forms of ANFH. The same gly1170-to-ser mutation was found
in two separate families, with the mutant allele occurring on dif-
ferent haplotype backgrounds. In the third family, a gly717-to-
ser mutation was detected. No mutation was found in the
COL2A1 coding region in sporadic cases of ANFH. The au-
thors pointed out that in families with ANFH, haplotype and se-
quence analysis of the COL2A1 gene can be used to identify
carriers of the mutant allele before the onset of clinical symp-
toms, allowing the initiation of measures that may delay pro-
gression of the disease (20). 
Finally, as endothelial nitric oxide synthase (eNOS) has bene-
ficial effects on skeletal, vascular and thrombotic systems, the
association between non traumatic femoral head osteonecro-
sis and eNOS polymorphisms has been investigated (21). Mi-
crosatellite polymorphism in intron 4 of eNOS gene was signif-
icantly associated with idiopathic femoral head osteonecrosis
in Korean patients indicating a possible protective role of nitric
oxide in the pathogenesis of the disease (20). 
In conclusion, some results suggest that defective cartilage
function or abnormal bone homeostasis, for example due to
COL2A1 gene mutations, could play a role in the pathogene-
sis of osteonecrosis. These genetic studies provide hope that
tools for identifying high risk patients will be available in the
future. 
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